March 13 (Reuters) - Mallinckrodt MCKPF.PK and Endo NDOI.PK, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion, the companies said on Thursday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.